Company intelligence / Profile preview
Bioviac
- Ownership
- Private
- Development stage
- Other
01
Overview
Bioviac is an early-stage biotechnology company focused on the discovery and development of novel therapeutic agents. The company leverages its expertise in medicinal chemistry and molecular biology to target unmet medical needs in oncology and infectious diseases. Bioviac's current efforts are centered on identifying high-affinity small molecule inhibitors with favorable pharmacokinetic profiles. While the company remains in the pre-clinical phase, it aims to advance its lead candidates toward IND-enabling studies to address critical gaps in current treatment paradigms.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Bioviac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioviac.